- Home
- AUPH
as 11-15-2024 4:00pm EST
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
| Founded: | 1993 | Country: | Canada |
| Employees: | N/A | City: | EDMONTON |
| Market Cap: | 1.0B | IPO Year: | 1999 |
| Target Price: | $10.33 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.71 - $10.05 | Next Earning Date: | 11-07-2024 |
| Revenue: | $220,361,000 | Revenue Growth: | 38.72% |
| Revenue Growth (this year): | 36.52% | Revenue Growth (next year): | 19.02% |
Stock Insider Trading Activity of Aurinia Pharmaceuticals Inc (AUPH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Karen L. | AUPH | Director | Nov 8 '24 | Sell | $8.43 | 5,241 | $44,181.63 | 12,672 | |
| Bailey Jeffrey Allen | AUPH | Director | Nov 8 '24 | Sell | $8.43 | 4,557 | $38,415.51 | 13,356 |
Latest Aurinia Pharmaceuticals Inc News
AUPH Breaking Stock News: Dive into AUPH Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
Business Wire
3 days ago
Aurinia to Participate in Jefferies London Healthcare Conference
MT Newswires
6 days ago
RBC Adjusts Aurinia Pharmaceuticals' Price Target to $9 From $8, Keeps Outperform Speculative Risk Rating
Pharmaceutical Technology
9 days ago
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets
TipRanks
9 days ago
Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring
GuruFocus.com
9 days ago
Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
MT Newswires
10 days ago
Aurinia Pharmaceuticals Reports Q3 Beat, Plans to Cut Workforce by 45%; Shares Rise
Zacks
10 days ago
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates
Compare AUPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUPH Aurinia Pharmaceuticals Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.